Limbix Spark is a 5-week standalone smartphone program based on cognitive behavioral therapy that is intended to treat adolescent depression, a mental health disorder that currently impacts over 3 million youth in the USA. Spark is currently undergoing clinical trials and will be available for providers to prescribe to patients starting in October 2021 under the FDA Discretionary Enforcement. Spark is intended for primary care as first line treatment for adolescent depression or as an alternative or adjunct to antidepressant treatment.
Limbix is a Silicon Valley startup developing clinically effective apps for adolescents with mental health disorders. Limbix is passionate about creating clinically effective apps for youth and young adult mental health treatment. The Limbix team is uniquely suited to develop clinically effective apps, as its diverse team of product designers, engineers, researchers, and clinicians understand the value of pairing clinical expertise with technological innovation. For more information visit limbix.com.